Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor

Brecanavir (BCV, 640385) is a novel, potent protease inhibitor (PI) with low nanomolar 50% inhibitory concentrations against PI-resistant human immunodeficiency virus (HIV) in vitro. This phase I, double-blind, randomized, placebo-controlled, two-part single-dose study (first time with humans) was c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ford, Susan L., Reddy, Y. Sunila, Anderson, Maggie T., Murray, Sharon C., Fernandez, Pedro, Stein, Daniel S., Johnson, Mark A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2006
Assuntos:
Clinical Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1479152/
https://ncbi.nlm.nih.gov/pubmed/16723584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01490-05
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares